You are here: Industry Insights > Zynteglo

News List

bluebird bio re-evaluates gene therapy strategy in ‘untenable’ European market pharmatimes
August 12, 2021
Among a second quarter results announcement full with setbacks, bluebird bio has revealed that it will exit the European market after failing to secure access for its gene therapy with various governments.
bluebird bio’s beta-thalassaemia gene therapy rejected by NICE pharmatimes
February 20, 2021
bluebird bio’s beta-thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s National Institute of Health and Care Excellence (NICE) for use on the NHS.
apceth Starts Commercial Manufacturing of Zynteglo™ ▼, bluebird bio’s Gene Therapy for Transfusion-Dependent β-Thalassemia b3cnewswire
January 17, 2020
apceth Biopharma GmbH, a subsidiary of Hitachi Chemical Co., Ltd. and a leading company for the manufacturing of cell and gene therapeutics, starts the commercial manufacturing of Zynteglo™ ▼, a product of bluebird bio, Inc. bluebird bio announced ...
apceth, bluebird bio Enter Mfg. Tie-up contractpharma
June 10, 2019
apceth to operate as the commercial manufacturer in Europe for Zynteglo, bluebird bio’s gene therapy for β-thalassemia.
EC grants conditional approval for bluebird bio’s Zynteglo pharmaceutical-technology
June 05, 2019
The European Commission (EC) has granted conditional marketing authorisation to bluebird bio’s gene therapy Zynteglo for the treatment of transfusion-dependent β-thalassemia (TDT).
Bluebird bags EU conditional marketing authorisation for Zynteglo pharmatimes
June 05, 2019
Bluebird bio has announced that its gene therapy Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) has been granted conditional marketing authorisation in Europe for certain patients 12 years and older with transfusion-dependent β-thalassaemi